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GS2.2 Treatment endpoints for HBV
C.-J. Liu *. Graduate Institute of Clinical Medicine,
Hepatitis Research Center and Department of Internal
Medicine, National Taiwan University College of Medicine
and Hospital, Taipei, Taiwan
Chronic hepatitis B virus (HBV) infection is still a
major health problem worldwide. In the past decade,
much progress has been made in the understanding and
management of chronic HBV infection and related liver
diseases. Most importantly, the introduction of universal
vaccination has signiﬁcantly reduced the incidence of
perinatal new HBV infection in most countries. In the
past decade, there have also been great advances in
the development of anti-viral therapy. Ideally, therapies
would be able to prevent adverse clinical outcomes such
as the development of cirrhosis, end-stage liver disease
and hepatocellular carcinoma. However, these clinical
endpoints typically take decades to occur and are therefore
impractical targets for clinical practice. As a result,
certain surrogate biomarkers that correlate with long-term
outcomes are frequently used to evaluate efﬁcacy of anti-
viral therapy. Of the serological and virological endpoints
that have been used, none has been shown to be ideal.
Suppression of viral replication, as measured by serum HBV
DNA levels, has been a major goal of therapy. Although
useful, the signiﬁcance of viral levels depends on the
stage of disease, degree of liver damage, and the type
of therapy. Besides, rebound of serum HBV DNA may occur
in a large proportion of patients receiving oral antiviral
agent. Hepatitis B e antigen (HBeAg) seroconversion is
still an important treatment endpoint in HBeAg-positive
patients. However, the durability of nucleos(t)ide analogue
treatment-related HBeAg seroconversion is not satisfactory;
and the emergence of HBeAg-negative disease is another
concern. Loss of hepatitis B surface antigen (HBsAg) is
considered close to the cure of the disease and is associated
with improved clinical outcomes; nevertheless it is rarely
achieved with current anti-vial therapies. Finally, liver
biopsy, traditionally considered as the gold standard, is
invasive, prone to sampling error, and not accepted by many
patients. In short summary, there is no ideal biomarker for
the evaluation of therapy for chronic hepatitis B. Patients
should be carefully monitored after stopping anti-viral
drugs. Challenges remain in the development of criteria for
treatment cessation and best treatment endpoints. HBsAg
quantitation is now being actively investigated for its role
in determining the natural history of CHB and whether the
on-treatment kinetics could predict response to anti-viral
therapy. The beneﬁt and limitations of using these endpoints
will be presented in this meeting.
GS2.3 Management of CHB patients: Considerations for
the difﬁcult cases and special populations
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CS14.1 The risk of hepatocellular carcinoma in
HCV-related chronic hepatitis
M. Omata*. Yamanashi Central Hospital and University of
Tokyo, Japan
For the last 20 years, we are trying to elucidate the
natural courses of HCV infections from acute hepatitis to
the development of Hepatocellular Carcinoma. We have
followed 3000 patients almost 15 years, and it was found
that the progression of ﬁbrosis is a key component to
develop hepatocellular Carcinoma.
Furthermore, the eradication of HCV virus in fact regress
the extend ﬁbrosis and eventually reduce the cancer risk.
Recent molecular diagnostic analysis revealed certain
SNPs may predict the outcome of the development
of Hepatocellular Carcinoma by GWAS ( Genome Wide
Association Study). The genetic analysis may help us to
identify the individuals to the development Hepatocellular
Carcinoma more precisely in the future.
These strategies, along with the improvement of treatments
by themselves, are actually ending up now to the gradual
reduction of the Hepatocellular Carcinoma death in Japan.
CS14.2 Risk assessment of HBV-related HCC
development using liver stiffness measurement
S.U. Kim*. Department of Internal Medicine, Institute of
Gastroenterology, Yonsei University College of Medicine,
Seoul, Korea
Background and Aims: Liver stiffness measurement (LSM)
using FibroScan accurately assesses the degree of liver
ﬁbrosis and the risk of hepatocellular carcinoma (HCC)
development in patients with chronic hepatitis C. This study
investigated the usefulness of LSM as a predictor of HCC
development in patients with chronic hepatitis B (CHB).
Methods: A total of 1,130 patients with non-biopsy-proven
CHB who underwent LSM between May 2005 and December
2007 were enrolled in this prospective study. After LSM was
performed, patients attended regular follow-up as part of
a surveillance program for the detection of HCC.
Results: The mean age of the patients (767 men, 363
women) was 50.2 years, and the median LSM was 7.7 kPa.
Six hundred seventy-two (59.5%) patients received antiviral
treatment before or after enrollment. During the follow-up
period (median, 30.7 months; range, 24.0 50.9 months),
HCC developed in 57 patients (2.0% per 1 person-year).
The 1-, 2-, and 3-year cumulative incidence rates of HCC
were 0.80%, 3.26%, and 5.98%, respectively. On multivariate
analysis, together with old age, male sex, heavy alcohol
consumption (>80 g/day), serum albumin, and hepatitis B
e antigen positivity, patients with a higher LSM (>8 kPa)
were at a signiﬁcantly greater risk of HCC development,
with the following hazard ratios: 3.07 (95% conﬁdence
interval [CI], 1.01 9.31; P = 0.047) for LSM 8.1 13 kPa; 4.68
(95%CI, 1.40 15.64; P = 0.012) for LSM 13.1 18 kPa; 5.55
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(95%CI, 1.53 20.04; P = 0.009) for LSM 18.1 23 kPa; and
6.60 (95%CI, 1.83 23.84; P = 0.004) for LSM > 23 kPa.
Conclusion: Our data suggest that LSM could be a useful
predictor of HCC development in patients with CHB.
Acknowledgement: This study was supported by a grant
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Ministry of Knowledge Economy, and by the Good Health R&D
Project, Ministry for Health, Welfare, and Family Affairs,
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CS14.3 The potential of genetically modiﬁed T cells to
prevent HBV related HCC
A.J. Gehring*. Department of Infection and Immunity,
Singapore Institute for Clinical Sciences, Agency for
Science, Techonlogy and Research (A*STAR), Singapore
Hepatocellular carcinoma (HCC) that develops in chronic
hepatitis B patients can express viral antigens from
chromosomally integrated hepatitis B virus (HBV) DNA.
Virus-speciﬁc T cells that could control HBV and eliminate
HCC expressing viral antigen are deleted or dysfunctional
in chronic patients. We have used T cell receptor (TCR)
gene transfer to reconstitute antiviral T cell immunity
in chronic HBV patients with the hope of developing a
cell-based therapy to target HBV-HCC and the underlying
chronic HBV infection. Using retroviral vectors we can
introduce HBV-speciﬁc TCRs into chronic HBV patient T
cells. We measure TCR expression using HLA-pentamers
and transduced T cell function by intracellular cytokine
staining, cytotoxicity and using a xenograft model of HCC
((gc)Rag2 / mice). The introduced TCRs are efﬁciently
expressed on the cell surface and result in polyfunctional
T cells (IFN-g, TNF-a, IL-2, Mip-b, MIP-a, IL-17, GM-CSF,
IL-8) that can lyse hepatocyte-like cell lines expressing
cognate HBV antigens. Adoptive transfer of TCR-redirected
T cells in the xenograft HCC model prevents formation of
the transplanted tumors and eliminates established tumors,
demonstrating their in vivo functionality. Furthermore, HBV-
speciﬁc TCR-redirected T cells can recognize Hep3B and
PLC-PRF5, HCC lines with natural HBV-DNA integration,
demonstrating they can respond to tumors expressing
viral antigen. Thus, TCR gene transfer can generate large
numbers of multifunctional HBV-speciﬁc T cells from chronic
HBV patient lymphocytes that are capable of recognizing
HBV infected hepatocytes and HCC tumor cells expressing
viral antigens from naturally integrated HBV genomes. These
genetically modiﬁed T cells could potentially be used to
reconstitute virus-speciﬁc T cell immunity for adoptive cell
therapy in chronic HBV and target tumors in HBV-related
HCC patients.
CS14.4 Reevaluation of the carcinogenic signiﬁcance of
HBV integration in hepatocarcinogenesis
S.Z. Jiang1,2, Z.W. Yang1, X.J. Li1, W.J. Li1, Y.F. Wang1,
J.B. Zhang1, J.L. Hou2, X.M. Chen1, H. Zhuang1, F.M. Lu1 *.
1Infection Disease Center & Department of Microbiology,
Peking University Health Science Center, Beijing 100191,
China, 2Southern Medical University, Guangzhou 510515,
China
Aims: To re-evaluate the carcinogenic signiﬁcance of
hepatitis B virus (HBV) integration in hepatocarcinogenesis.
Methods: Viral host genome junction sequences in both
tumor and paired corresponding non-tumor tissues from
HCC patients with chronic HBV infection were analyzed
using cassette ligation-mediated PCR (LM-PCR) and Alu-PCR
and direct sequencing. The integration sites were mapped
based on the acquired ﬂank sequence of human genome.
The potentially affected genes (interrupted directly by
integration or mapped within 100kb up- or downstream
of the viral-host junctions) were clustered based on their
function via gene ontology (GO) were performed to cluster
analysis. The somatic mutation and loss of heterogeneity
(LOH) of TP53 were screened by direct sequencing.
Array-based comparative genomic hybridization (aCGH) was
performed to detect the chromosomal aberrations in tumor
tissues.
Results: Collectively, a total of 232 different viral-
host sequences were identiﬁed in 68% (34/50) of tumor
and 70% (35/50) of non-tumor tissues. Among them,
chromosomal locations were determined in 87.52% (71/84)
of integrations in tumor tissues and 82.43% (122/148)
in non-tumor tissues, respectively. The viral-insert sites
were evenly distributed in all chromosomes including
X and Y. However, 35.71% (30/84) of integrants were
found within either exonic or intronic sequences of a
host gene in tumor tissues, and 35.13% (52/148) in non-
tumor tissues. Further GO annotation revealed that the
affected genes were enriched in transcription regulation
(9/31) and nucleus (12/31) with statistically signiﬁcant.
Such enrichment was not observed in non-tumor. Of 179
genes in tumor and 313 in non-tumor, which mapped
within 100 kb up- or downstream from or interrupted by
the HBV integration, GO annotation demonstrated that
genes involved in metabolism, transcription, and DNA-
binding were more enriched in tumor than in non-tumor.
In particular, 23.46% (42/179) genes were related with
transcription in tumor, but few genes were discovered in
non-tumor. When regarding to the HBV genome, 59.48%
(138/232) integrants contained X region sequences, 40.52%
(94/232) integrants contained pre C/C region sequences.
The break points of the integrants were mainly distributed
between the DR1 and DR2 of HBV. The percentages of 3′
deleted X gene caused by integration were 97.96% (48/49)
in tumor and 95.51% (85/89) in non-tumor tissues (p > 0.05).
Further analysis of these integrated 3′ truncated X gene
via immunohistochemistry assay detected few expression of
HBx in tumor. In addition, data from aCGH study indicated
that no direct correlation between chromosome instability
and HBV integration, while mutations or LOH of TP53 were
found in most tumor tissues with greater chromosome
instability.
Conclusions: HBV DNA integration could be observed in
both tumor and non-tumor tissues, with similar rates of
HBV C or X region integration. A similar frequency of
integrated X gene 3′ truncated deletion in tumor and
corresponding non-tumor tissues did not support a role
in hepatocarcinogenesis. Chromosomal instability (CIN) has
no prominent correlation with HBV integration. GO analysis
showed that genes located surrounding or interrupted by
the HBV integration in tumor tissues were clustered with
functions more relevance to transcription, nucleus and so
on, indicating that HBV integration affecting the expression
of the nearby genes is a previously unrevealed molecular
mechanism leading to cell malignant transformation.
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